Joint Corp (JYNT) Gets a Buy Rating from Maxim Group

Maxim Group analyst Anthony Vendetti maintained a Buy rating on Joint Corp (JYNT) today and set a price target of $11. The company’s shares closed yesterday at $7.98.

Vendetti said:

“Market close, JYNT reported relatively inline 3Q18 results and maintained 2018 financial guidance. The company opened 10 franchise clinics in 3Q18 and closed one, for a total of 374. Its corporate clinic count remained steady at 48. The company appointed Jake Singleton as its new CFO. He has served as Corporate Controller at JYNT since June 2015. We are introducing quarterly estimates for 2019.”

According to, Vendetti is a 5-star analyst with an average return of 11.5% and a 55.9% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Ellex Medical Lasers Limited, Restoration Robotics Inc, and Ra Medical Systems Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Joint Corp with a $11 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $9.64 and a one-year low of $4.67. Currently, Joint Corp has an average volume of 35.92K.

Based on the recent corporate insider activity of 13 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

The Joint Corp. (United States) engages in the development, ownership, operation, support and management of chiropractic clinics. It operates through the Corporate Clinics and Franchise Operations segments. The Corporate Clinics segment comprises of the operating activities of the company owned or managed clinics.